Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
-
BUSINESS Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
-
ORGANIZATION Japan Logs 10th Consecutive Year of Decrease in Drug Reps, Hefty Dip in 2023
July 25, 2024
-
BUSINESS Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
-
REGULATORY LDP Policy Panel OKs FY2025 Budget Guidelines, Lower Cap Likely for “Natural Increase”
July 24, 2024
-
BUSINESS Axcelead-Teijin JV Anticipates Synergies in Common Disease Areas, Pipelines
July 23, 2024
-
BUSINESS Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
-
REGULATORY Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
-
REGULATORY MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
-
REGULATORY Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo
July 18, 2024
-
BUSINESS Insmed Set to Double Japan Staff by 2025-End as It Gears Up for Brensocatib Debut
July 17, 2024
-
BUSINESS LTL, Cheplapharm Envision Heightened Opportunities for LLP Takeovers under Elective Care Scheme
July 16, 2024
-
BUSINESS Meiji Paints Consortium Plan of Its Own, Woos Generic Peers to Join Scheme
July 16, 2024
-
BUSINESS Chiesi Joins Japan Rare Disease Market, Shoots for 10 Billion Yen Sales by 2030
July 12, 2024
-
BUSINESS FY2023 Logs Gyration in COVID Drug Sales, Stark Contrast for Ronapreve, Lagevrio
July 11, 2024
-
REGULATORY Japan Wants to Spur Regulatory Use of RWD, but Still Puts Weight on RCTs
July 10, 2024
-
REGULATORY PMDA to Push Simultaneous Development of Pediatric Drugs via New Consultation Center
July 9, 2024
-
BUSINESS Moderna Medical Chief Voices Excitement for Flu-COVID Jab; Japan PIII Set to Kick Off by Year’s End
July 9, 2024
-
REGULATORY MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
July 8, 2024
-
REGULATORY Panelists Wary of Proposed Switch of Generic GMP Inspection Authority to PMDA
July 8, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…